Literature DB >> 33411788

Aberrant regulation of a poison exon caused by a non-coding variant in a mouse model of Scn1a-associated epileptic encephalopathy.

Yuliya Voskobiynyk1, Gopal Battu2, Stephanie A Felker2,3, J Nicholas Cochran2, Megan P Newton4, Laura J Lambert4, Robert A Kesterson4, Richard M Myers2, Gregory M Cooper2, Erik D Roberson1, Gregory S Barsh2.   

Abstract

Dravet syndrome (DS) is a developmental and epileptic encephalopathy that results from mutations in the Nav1.1 sodium channel encoded by SCN1A. Most known DS-causing mutations are in coding regions of SCN1A, but we recently identified several disease-associated SCN1A mutations in intron 20 that are within or near to a cryptic and evolutionarily conserved "poison" exon, 20N, whose inclusion is predicted to lead to transcript degradation. However, it is not clear how these intron 20 variants alter SCN1A expression or DS pathophysiology in an organismal context, nor is it clear how exon 20N is regulated in a tissue-specific and developmental context. We address those questions here by generating an animal model of our index case, NM_006920.4(SCN1A):c.3969+2451G>C, using gene editing to create the orthologous mutation in laboratory mice. Scn1a heterozygous knock-in (+/KI) mice exhibited an ~50% reduction in brain Scn1a mRNA and Nav1.1 protein levels, together with characteristics observed in other DS mouse models, including premature mortality, seizures, and hyperactivity. In brain tissue from adult Scn1a +/+ animals, quantitative RT-PCR assays indicated that ~1% of Scn1a mRNA included exon 20N, while brain tissue from Scn1a +/KI mice exhibited an ~5-fold increase in the extent of exon 20N inclusion. We investigated the extent of exon 20N inclusion in brain during normal fetal development in RNA-seq data and discovered that levels of inclusion were ~70% at E14.5, declining progressively to ~10% postnatally. A similar pattern exists for the homologous sodium channel Nav1.6, encoded by Scn8a. For both genes, there is an inverse relationship between the level of functional transcript and the extent of poison exon inclusion. Taken together, our findings suggest that poison exon usage by Scn1a and Scn8a is a strategy to regulate channel expression during normal brain development, and that mutations recapitulating a fetal-like pattern of splicing cause reduced channel expression and epileptic encephalopathy.

Entities:  

Year:  2021        PMID: 33411788      PMCID: PMC7790302          DOI: 10.1371/journal.pgen.1009195

Source DB:  PubMed          Journal:  PLoS Genet        ISSN: 1553-7390            Impact factor:   5.917


  51 in total

1.  Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer's disease.

Authors:  Alicia M Hall; Benjamin T Throesch; Susan C Buckingham; Sean J Markwardt; Yin Peng; Qin Wang; Dax A Hoffman; Erik D Roberson
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

2.  Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel.

Authors:  Elaine C Wirrell; Linda Laux; Elizabeth Donner; Nathalie Jette; Kelly Knupp; Mary Anne Meskis; Ian Miller; Joseph Sullivan; Michelle Welborn; Anne T Berg
Journal:  Pediatr Neurol       Date:  2017-02-04       Impact factor: 3.372

Review 3.  Sodium channel SCN1A and epilepsy: mutations and mechanisms.

Authors:  Andrew Escayg; Alan L Goldin
Journal:  Epilepsia       Date:  2010-09       Impact factor: 5.864

4.  Impaired action potential initiation in GABAergic interneurons causes hyperexcitable networks in an epileptic mouse model carrying a human Na(V)1.1 mutation.

Authors:  Ulrike B S Hedrich; Camille Liautard; Daniel Kirschenbaum; Martin Pofahl; Jennifer Lavigne; Yuanyuan Liu; Stephan Theiss; Johannes Slotta; Andrew Escayg; Marcel Dihné; Heinz Beck; Massimo Mantegazza; Holger Lerche
Journal:  J Neurosci       Date:  2014-11-05       Impact factor: 6.167

5.  Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy.

Authors:  Frank H Yu; Massimo Mantegazza; Ruth E Westenbroek; Carol A Robbins; Franck Kalume; Kimberly A Burton; William J Spain; G Stanley McKnight; Todd Scheuer; William A Catterall
Journal:  Nat Neurosci       Date:  2006-08-20       Impact factor: 24.884

6.  Sudden unexpected death in a mouse model of Dravet syndrome.

Authors:  Franck Kalume; Ruth E Westenbroek; Christine S Cheah; Frank H Yu; John C Oakley; Todd Scheuer; William A Catterall
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

7.  Evidence for a direct role of the disease modifier SCNM1 in splicing.

Authors:  Viive M Howell; Julie M Jones; Sarah K Bergren; Li Li; Allison C Billi; Matthew R Avenarius; Miriam H Meisler
Journal:  Hum Mol Genet       Date:  2007-07-26       Impact factor: 6.150

8.  Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice.

Authors:  Anthony J Filiano; Lauren Herl Martens; Allen H Young; Brian A Warmus; Ping Zhou; Grisell Diaz-Ramirez; Jian Jiao; Zhijun Zhang; Eric J Huang; Fen-Biao Gao; Robert V Farese; Erik D Roberson
Journal:  J Neurosci       Date:  2013-03-20       Impact factor: 6.167

Review 9.  Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening.

Authors:  Aliesha Griffin; Kyla R Hamling; SoonGweon Hong; Mana Anvar; Luke P Lee; Scott C Baraban
Journal:  Front Pharmacol       Date:  2018-06-04       Impact factor: 5.810

10.  Poison-Exon Inclusion in DHX9 Reduces Its Expression and Sensitizes Ewing Sarcoma Cells to Chemotherapeutic Treatment.

Authors:  Ramona Palombo; Veronica Verdile; Maria Paola Paronetto
Journal:  Cells       Date:  2020-01-31       Impact factor: 6.600

View more
  2 in total

Review 1.  Exploring the Diverse Functional and Regulatory Consequences of Alternative Splicing in Development and Disease.

Authors:  M Brandon Titus; Adeline W Chang; Eugenia C Olesnicky
Journal:  Front Genet       Date:  2021-11-24       Impact factor: 4.599

Review 2.  Gene Editing and Modulation: the Holy Grail for the Genetic Epilepsies?

Authors:  Jenna C Carpenter; Gabriele Lignani
Journal:  Neurotherapeutics       Date:  2021-07-07       Impact factor: 7.620

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.